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Bleomycin-Induced Lung Injury in the
Rat: Effects of the Platelet-Activating
Factor (PAF) Receptor Antagonist
BN 52021 and Platelet Depletion
by Timothy W. Evans,* Robin J. McAnulty,*
Duncan F. Rogers,* K. Fan Chung,* Peter J. Barnes,*
and Geoffrey J. Laurent*
Bleomycinisahighly effective antitumoragent, but pulmonary toxicity, characterizedby anacute
inflammatory reactionandassociatedpulmonary edema, limits clinical use ofthedrug. Plateletsand
platelet-activating factor (PAF), a membrane-derived phospholipid, have been implicated in the
mechanismsthatcanmediatepulmonarymicrovascularinjury. WesoughttoinvestigatetheroleofPAF
inbleomycin-inducedlunginjury inthe rat, usingthePAFreceptorantagonist BN 52021; andtherole
of platelets though the use of an anti-platelet antibody. Lung injury was induced by intratracheal
bleomycin(1.5mg)andassessedbymeasurementsoflungwetweightandtotalpulmonaryextravascular
albuminspace(TPEAS). Bleomycincausedasignificantincreaseinbothindicesafter48hr, compared
withcontrolanimals(p < 0.05). AsingledoseofBN52021 (20mg/kgorally) significantlyreducedthe
bleomycin-induced increase inlungweight, but not the rise inTPEAS (p > 0.05). Increasingthe dose
ofBN 52021 (20 mg/kg/12 hr, orally) had no additional effect. Reducing circulating platelet numbers
by approximately 75% had no effect on either the increase in lung weight or TPEAS, observed 48 hr
afterbleomycin(p > 0.05). PAFmaypartiallycontributetotheacuteinfiamtoryreactionseenafter
intratracheal bleomycin in rats.
Introduction
Bleomycin, an antibiotic derived from Streptomyces
vertillus, is ahighly effective antitumor agentthat is
widelyusedinthetreatmentoflymphomaandtesticular
and squamous cell tumors (1). Pulmonary toxicity is a
prominentsideeffectofthedrug, limitingthedosethat
may be used in clinical practice. In severely affected
patients, a pneumonitis may develop similar to that of
the adult respiratory distress syndrome (ARDS),
characterized by increased vascular permeability,
pulmonaryedema, andrefractoryhypoxemiawithahigh
associated mortality(2-4). Although severalconditions
predispose the lung to injury-including doses of
bleomycininexcessof450mg, concomitant exposureto
radiation, combination therapy with other agents, and
impaired renal function-the mechanisms underlying
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thepulmonarytoxicityremainunknown(5). Similarities
in pathology and clinical presentation between
bleomycin-inducedlunginjuryandARDSsuggestacom-
mon etiology (5,6).
Bleomycin administered intratracheally in rats has
beenshown, inourlaboratoryandthoseofothers, topro-
ducehistologicalchangessimilartothoseseeninARDS
(6). These comprise an early inflammatory phase
characterized by neutrophil influx and increased
microvascularpermeability, maximalafter72hr(7), and
followedbyfibrosisthat is maximal at 2 to 3 weeks(8).
Manypreviousinvestigatorshavefocusedontheroleof
vasoactive substances and inflammatory cells in
generatingacuteedematouslunginjury(9,10). Platelet-
activating factor (PAF) is a membrane-derived
phospholipid that hasbeen shown to mediate both the
pulmonarymicrovascularinjuryandacuteinflammatory
changesthatfollowadministeringendotoxintorats(11).
In a previous study, we have also shown PAF to be a
potent mediator of increased vascular permeability in
thebronchialcirculationoftheguineapig, aneffectthat
can be abolished using a PAF-receptor antagonist, theEVANSETAL.
ginkgolide mixtureBN 52063(12). Thesequestrationof
platelets in the lungs of patients with ARDS, together
with experimental evidence to suggest that platelets
may directlydamagealveolarcapillarymembranesand
intereact with neutrophils to produce inflammatory
mediators, has also led to speculation regarding their
potentialroleinthegenerationofacutelunginjury(10).
Inthecurrentstudy, wethereforeinvestigatedtheef-
fects of the ginkgolide PAF-receptor antagonist BN
52021, whichistheactivecomponentofBN52063, and
ofplateletdepletionontheacute(inflammatory)phase
of bleomycin-induced lung injury in the rat.
Methods
Male Lewis rats (175-225 g, Charles River, UK) were
anesthetized with intramuscular Hypnorm (fentanyl
citrate0.315mg/mLandfluanisone 10mg/mL)atadose
of0.5to 1.0mL/kgbodyweight,priortoeachprocedure.
Intratracheal Bleomycin
Animals received 1.5 mg of bleomycin in 0.3 mL of
0.9% salinebyintratrachealinstillation. Controlanimals
received 0.3 mLofsaline alone. Animals were sacrific-
ed 48 hr after receiving bleomycin.
Administration of BN 52021
BN 52021,20mg/kgin0.5% carboxymethylcellulose
(20mg/mL), wasadministeredbygavageatvaryingtime
intervals. Controlanimalsreceived0.5% carboxymethyl
cellulose alone (1 mL/kg).
Assessment of Tbtal Pulmonary
Extravascular Albumin Space
Totalpulmonaryextravascularalbuminspace(TPEAS)
was measured using a method modified from that of
Wangensteen etal. (13)anddescribed infullelsewhere
(6). Twenty-four hours before being sacrificed, each
animalreceived 1 to 2IACi of 125I-labeled human serum
albumin(AmershamInternationalLtd., UK)IVviaatail
vein, in a total volume of 0.5 mL of 0.9% saline. The
animals were anesthetized and exsanguinated via the
aorta24 hrlater. The pulmonary circulation wasflush-
ed free of blood by ligating a cannula within the right
ventricle and perfusing with 12 mL of phosphate-
bufferedsaline. Thelungs wereremovedand dissected
free ofthe main bronchi and blood vessels. They were
gentlyblottedtoremoveexcesssurfacefluid, weighed,
and placed in a counting vial. Duplicates of 0.1 mL
plasma were also counted in a gamma counter. Total
pulmonaryextravascularalbuminspacewascalculated
as the ratio of total lung radioactivity to that of 1 mL
plasma.
Experimental Protocols
TheeffectofBN52021 onbleomycin-inducedlungin-
jury wasfirstassessedbyadministeringasingle doseof
drug(n = 7) orthe vehicle alone (n = 8) to rats 30 min
prior to receiving bleomycin. A third control group
received intratracheal saline (n = 5). All animals were
sacrificed 48 hr later.
To test for a possible dose-dependent effect of BN
52021, in a second experiment animals received BN
52021 (n = 9) orthe vehicle alone (n = 6)30 min prior
tothebleomycinandsubsequentlyat 12-hrintervalsup
to 48 hr, when they were sacrificed. A third, control
group received intratracheal saline (n = 3).
Tb assess the possible role of platelets in bleomycin-
induced lung injury, in a third experiment animals re-
ceived either 1.0 mL/kgrabbit serumby IP iWection(n
= 6), or1.0mL/kgoftherabbitanti-ratplateletantibody
(IP, n = 6)24hrpriortothebleomycin. Fullbloodcounts
were measured 24 hr later, and the animal were sacri-
ficed (as before) 48 hr after receiving the bleomycin.
Drugs and Chemicals
Drugs and chemicals were obtained from the follow-
ing sources: Hypnorm from Janssen Pharmaceuticals
(Oxford, UK); bleomycinfrom Lundbeck Pharmaceuti-
cals(UK); BN 52021 wasakindgiftfrom Dr. P. Braquet
(Laboratories HenriBeaufour, Paris, France); and anti-
platelet antibody a kind gift from Dr. K. Butler (Ciba
Laboratories, West Sussex, UK).
Statistical Methods
Comparisons between groups were made using the
Mann-Whitney Utest. Values less than 0.05 were con-
sidered significant.
Results
Wet weight and TPEAS for animals in experiment 1
areshowninFigure 1.Administrationofbleomycincaus-
ed a significant increase in lung weight and TPEAS in
both groups of animals, compared with controls (p <
0.05). AdministrationofthePAFreceptorantagonistBN
52021 caused a significant reduction in the increase in
lungweight compared withvehicle(1.09 ± 0.10, mean
± SEM, vs. 1.64 ± 0.19 g, p < 0.05). The increase in
TPEAS was attenuated by BN 52021, althoughthis did
notachievestatisticalsignificance(0.31 ± 0.05vs. 0.41
± 0.05, p < 0.05).
Data from the second study, in which animals were
givenmultipledosesofBN 52021, areshowninFigure 2.
Theincreaseinlungwetweightcausedbybleomycinwas
significantly altered by BN 52021 (1.17 + 0.04 vs. 1.33
+ 0.05, p < 0.05). The bleomycin-induced increase in
TPEAS was reduced with BN 52021, but, again, not
significantly so(0.57 ± 0.01 vs. 0.41 ± 0.02, p = 0.07).
The resultsforthe thirdstudy are shown in Figure 3.
Platelets were significantly (p < 0.05) reduced in
the antibody-treated group, compared with serum
(mean count 252 x 109/L vs. 947 x 109/b). Neither
hemoglobin nor white cell count were significantly
altered. There was no significant difference between
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FIGURE 1. Changes in lung weight and total pulmonary
extravascularalbuminspace(TPEAS)inratstreatedwithBN52021
20mg/kgor0.5% carboxymethyl cellulose(vehicle) orally30min
prior to receiving intratracheal bleomycin 1.5 mg or saline
(control) and perfused 48 hrlater. Horizontal barsindicate mean
values, Dagger(t)indicatessignificantincreasecomparedwithcon-
trol. Asterisk (*) indicates significant decrease compared with
bleomycin plus vehicle.
WEIGHT (G) TPEAS
FIGURE 3. Changes in lung weight and TPEAS in animals treated
withanti-plateletantibodyorserum, 12 hr beforetreatmentwith
BN52021 20mg/kgor0.5% carboxymethylcellulose(vehicle). In-
tratracheal bleomycin 1.5 mg was administered 30 min later.
Horizontal bars indicate mean values.
thegroupsforeitherlungweight(1.10 + 0.03forvehicle
vs. 1.19 ± 0.09 g for BN 52021 animals) or TPEAS
(0.46 ± 0.06 vs. 0.40 ± 0.06).
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FIGURE 2. Changesinlungweight and totalpulmonary extravascu-
laralbumin space(TPEAS) in ratstreated withBN52021 20mg/kg
or 0.5% carboxymethyl cellulose (vehicle) 30 min prior to in-
tratrachealbleomycin 1.5mgorsaline(control)andat 12-hrinter-
valsthereafter, andperfused after48hr. Horizontalbarsindicate
mean values. Dagger(t) indicates significant increase compared
with control. Asterisk(*)indicatessignificant decrease compared
with bleomycin plus vehicle.
Discussion
Anytherapeuticinterventionthatmightbedeveloped
by an understanding of the mechanisms underlying
bleomycin-induced lung injury would considerably
extendtheclinicaleffectivenessofthedrug. Ourresults
suggest that PAF may be partially responsible for the
acuteinflammatoryresponseseenafterintratrachealad-
ministration ofbleomycin inthe rat, although onlyone
ofthe measured indices, the lungweight, was affected
by administration of the drug.
Inpreviousstudieschangesinlungweighthavebeen
showntocorrelatewellwithacutelunginjuryandsubse-
quentfibrosis(14). Furtherattenuationoftheeffectsof
bleomycin was not achieved by increasing the dose of
BN 52021. Wepreviouslyshowed thatasmallerdose of
a less potent, but related PAF receptor antagonist, BN
52063, iscompletely effective inabolishingthe inflam-
matoryeffectsofexogenously administered PAF, asin-
dicatedbychangesinmicrovascularpermeabilityinthe
bronchialcirculationoftheguineapig(12). Interestingly,
although increasing the total dose of BN 52021 ad-
ministeredinthesecondexperimentdidnotfurtherat-
tenuatetheincreaseinlungweightseenafterbleomycin,
the reduction in TPEAS almost achieved statistical
significance (p = 0.07).
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Wagensteen et al. (13) have shown that intratracheal
bleomycin in the rat does not increase lung wet/dry
weightratio, suggestingthattheincreaseinlungweight
could be the result of inflammatory cell influx into the
lungs. Previousworkfromourlaboratoryshowedsignifi-
cantincreasesintherecoveryofinflammatorycellssuch
asneutrophils, lymphocytes, and monocytes inbroncho-
alveolar lavage fluid from rats that were treated with
bleomycin (6). It is possible that the PAFantagonist BN
52021 inhibits the chemotaxis of neutrophils into the
lungs since PAF possesses chemotactic effects for
neutrophils in vitro (15).
Our measurement of albumin space, TPEAS, is not
necessarily anindexofvascularpermeabilitytoalbumin
as shown by Wagensteen et al. (13). Indeed, by using a
new method for specifically assessing albumin
permeabilitytheyfoundonlyasmallsignificantincrease
after dosing with bleomycin, but TPEAS was approx-
imately doubled, as we observed in our present study.
It is possible that the increase in TPEAS is a reflection
of a direct effect of bleomycin on the lung interstitial
space that allows albumin to occupy more ofthe inter-
stitial volume. Presumably, neither PAF nor platelets
would effect this process. Thus, the two indices oflung
injury we measured may reflect different pathological
processes induced by bleomycin.
Despitethefailure ofBN52021 topreventpulmonary
injury in the rat model, PAF may still be a partial
mediatorofbleomycin-inducedlunginjuryinman. PAF
isoneofthemostpotentinflammatorymediatorsknown
to increase microvascular leakage in different vascular
beds in several animal species, and it has many of the
properties that can induce the pathophysiologic
responses of acute lung injury. Pulmonary endothelial
damagehasbeenobservedfollowingtheadministration
of PAF in several animal models, and it is indicated by
increasinglymphflow, elevatedlymphaticalbuminand
globulin content, and increased lung weight (16).
TheIVadministrationofPAFhasbeenshowntoalter
lung mechanics in rabbits and guinea pigs in a similar
mannertothatseenclinicallyinpatientswithbleomycin-
inducedpulmonaryinijuryandARDS(17,18). Endothelial
damage accompanied by platelet and leukocyte plugs
are alsoobserved inthepulmonarycapillariesofexperi-
mentalanimalsafterPAFadministration(19). However,
thereleaseofPAFduringinductionofacutelunginjury
in experimental animals has yet to be demonstrated,
possibly because of its short plasma half-life (20). The
biologicaleffectofPAFmaybeamplifiedbythepresence
ofothermediatorsreleased fromactivated neutrophils
and platelets. Such mediators include lysosomal en-
zymes, toxic oxygen radicals, thromboxane, and leuko-
trienes(21,22). It maybe that acombination ofantago-
niststoavarietyofmediatorsmayberequiredtoachieve
thefurtherblockadeofacutelunginjuryinthisandother
models. Forexample, in aprevious study, we were able
toonlypartiallyinhibitendotoxin-induced increasesin
airwaymicrovascular permeability in guineapigsusing
PAF receptor antagonists alone, suggesting that addi-
tional factors were involved (23).
Evidence suggests thatplatelets are acritical compo-
nentinthegeneration ofacutelungirjury(10). Insome
species, the release of vasoactive inflammatory
mediators is, at least, partially dependent upon the
presence ofplatelets(24), which togetherwith neutro-
philsreleaseinflammatorymediatorswhenactivatedby
endothelial-derived mediators such as PAF and throm-
boxane. Aggregation ofplatelets andneutrophils in the
lungs of experimental animals has been observed in
models of acute lung injury (21).
We were unable to show that a reduction in platelet
count caused any significant reduction in bleomycin-
inducedlunginjury. Thismayhavebeenduetoaninade-
quate reductioninplatelet numbers(approximately 75'%
inhibition), althoughthemaximaleffectoftheantibody
occurs 12 hrafteradministration, andtheplateletcounts
(measured at24hr)maythereforenothavereflectedthe
period of maximum suppression.
TheresultsofthepresentstudysuggestthatPAFmay
bepartlyinvolvedinmediatingbleomycin-induced acute
lunginjury in the rat, perhaps by inhibiting the inflam-
matorycellrecruitment. Nevertheless, itisincreasingly
clear from this and other investigations that no single
pathway leads directly towards acute edematous lung
injury. It is more likely that a large number of humoral
factors, inflammatory cells, andmediatorsinteractwith
other currently undefined agents to promote vascular
endothelial celldamage and respiratory failure. Conse-
quently, althoughfurtherstudies usingnewlyavailable
antagonists with greater potency (25) are indicated,
theseshouldpossiblybecarriedoutincombinationwith
depletion of inflammatory cells.
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